NCT05813249View on ClinicalTrials.gov

Semaglutide in Nonalcoholic Fatty Liver Disease

PHASE4CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

February 15, 2024

Study Completion Date

April 1, 2024

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

DRUG

Rybelsus Oral Product

Oral Semaglutide

DRUG

Ozempic Injectable Product

Subcutaneous Semaglutide

DRUG

Tocopherol and/or Actos

Vitamin E and/or Pioglitazone

Trial Locations (1)

44519

Zagazig University, Zagazig

All Listed Sponsors

lead

Zagazig University

OTHER_GOV